Physician profile
Joyce Fox
NPI 1710999297
$3,268.24
in general payments reported to CMS, 2019-2025
21 companies · $894 in 2025
The $894 reported for 2025 was more than what a typical Pediatric Dermatology provider received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $132 · 2021: $195 · 2022: $181 · 2023: $462 · 2024: $770 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,125.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $485.50 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $471.34 | 2024-2025 | |
| Galderma Laboratories, L.P. | $451.91 | 2019-2025 | Nemluvio |
| Janssen Biotech, INC. | $255.87 | 2021-2025 | Tremfya |
| Genzyme Corporation | $242.68 | 2019-2025 | |
| Incyte Corporation | $185.91 | 2021-2025 | Opzelura |
| Celgene Corporation | $173.00 | 2019 | |
| Lilly USA, LLC | $150.57 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $140.07 | 2024-2025 | Bimzelx |
| Argenx US, INC. | $125.00 | 2023 | Vyvgart |
| Sun Pharmaceutical Industries INC. | $117.61 | 2025 | |
| Leo Pharma INC. | $92.41 | 2020-2025 | Anzupgo, Adbry |
| Regeneron Healthcare Solutions, INC. | $88.95 | 2019-2024 | Dupixent, Libtayo |
| Pfizer INC. | $88.54 | 2020-2024 | |
| Allergan, INC. | $70.12 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $37.12 | 2023-2025 | |
| Dermira, INC. | $22.75 | 2020 | |
| Arcutis Biotherapeutics, INC. | $21.95 | 2025 | Zoryve |
| Almirall LLC | $20.26 | 2023 | Klisyri |
| Amgen INC. | $13.73 | 2025 | Otezla |
| Dermavant Sciences, INC. | $12.95 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.